1GLOBAL
22.2.2024 18:40:31 CET | Business Wire | Press release
The range of industries adopting 1GLOBAL’s innovative services continues to grow as more than 30 million European customers will be soon avoiding roaming charges in over 160 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222033843/en/
Data Roaming Without Worries, Now in Every App: eSIM Innovator 1GLOBAL gives FinTech its Own Roaming Service. (Graphic: Business Wire)
By fully integrating the 1GLOBAL API, global fintech Revolut now offers its customers simple, fast access to 1GLOBAL's low-cost global mobile network. Once activated by the user, an embedded SIM (eSIM) is generated for the mobile device.
"Without having to leave the Revolut app, users can install an eSIM within one minute,” said Hakan Koç, Founder and CEO of 1GLOBAL. “This is why players from a wide range of industries such as travel, insurance, fintech, airlines, VIP logistics and more are all coming to us to increase the range of services they offer by integrating our connectivity."
Instead of having to obtain a physical SIM to access the local network on arrival, customers using apps that integrate 1GLOBAL’s technology will simply set up an eSIM on their device. This gives them complete control of their connection, including a display of data consumption. They can also use the app to buy a data plan even when they’ve already run out of allowance.
”At Revolut, we know how important it is for our customers that they stay connected to Revolut services, wherever they are, without worrying about their data allowance. Revolut eSIMs, developed in partnership with 1Global, is a convenient technology and provides great value tailored to our global audience," commented David Tirado, Global Business VP at Revolut.
Any company can integrate 1GLOBAL tech into its own customer offering via a suite of APIs. As a result, customers stay within that app for longer, a new revenue channel is created, value for customers is generated and brand loyalty increased.
In Revolut’s case, full integration of 1GLOBAL technology was made into its own app and under its own brand. Alternatively, companies can offer 1GLOBAL connectivity simply as a 3rd party or affiliate via references (such as a QR code) that directs the user to download their eSIM and 1GLOBAL software.
"As a telecommunications technology innovator, we have created our own global telecommunications network and can issue eSIMs and an International Mobile Subscriber Identity (IMSI),” explains Koç. “This distinguishes us from vendors who do not have their own network infrastructure and simply resell data packages.”
The 1GLOBAL platform gives app operators the ability to offer users global connection supported by nine Mobile Virtual Network Operators (MVNO), five international sponsored roaming partners, and over 150 interconnects. This kind of ‘hyperscale’ connectivity, with 2000 routes to 350 mobile carriers spanning 2G to 5G and LPWAN, would be impossible without leveraging 1GLOBAL’s innovative technology.
About 1GLOBAL
1GLOBAL provides quick and secure mobile network connectivity in over 160 countries worldwide. Their eSIM technology integrates seamlessly into the existing Revolut app and can be installed on any eSIM-compatible mobile device in less than a minute.
Founded in 2022, 1GLOBAL is the new startup of Hakan Koç, co-founder and former Co-CEO of AUTO1 Group. 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognised, GSMA-accredited global mobile network. Headquartered in London, with an R&D hub in Lisbon, they have now grown to include over 400 employees across 12 countries and have been granted fully regulated MVNO status in nine of them.
About Revolut
Revolut is a global fintech, helping people get more from their money. In 2015, Revolut launched in the UK offering money transfer and exchange. Today, more than 35 million customers around the world use dozens of Revolut’s innovative products to make more than half a billion transactions a month.
Across our personal and business accounts, we give customers more control over their finances and connect people seamlessly across the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222033843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom